Bioluminescent kinase strips: A novel approach to targeted and flexible kinase inhibitor profiling

被引:9
|
作者
Hennek, J. [1 ,4 ]
Alves, J. [1 ]
Yao, E. [2 ]
Goueli, S. A. [1 ,3 ]
Zegzouti, H. [1 ]
机构
[1] Promega Corp, R&D Dept, Madison, WI 53711 USA
[2] SignalChem Pharmaceut, Richmond, BC V6V 2J2, Canada
[3] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pathol & Lab Med, Madison, WI 53705 USA
[4] Exact Sci, Madison, WI 53719 USA
关键词
Kinase profiling; Bioluminescence; ADP detection; Selectivity profiles; Kinase assay; Kinase inhibitor; CHRONIC MYELOGENOUS LEUKEMIA; PROTEIN-KINASE; RHEUMATOID-ARTHRITIS; DRUG DISCOVERY; SELECTIVITY; ASSAY; MOUSE; MAP; CK2; GLOMERULONEPHRITIS;
D O I
10.1016/j.ab.2015.11.007
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
In addition to target efficacy, drug safety is a major requirement during the drug discovery process and is influenced by target specificity. Therefore, it is imperative that every new drug candidate be profiled against various liability panels that include protein kinases. Here, an effective methodology to streamline kinase inhibitor profiling is described. An accessible standardized profiling system for 112 protein kinases covering all branches of the kinome was developed. This approach consists of creating different sets of kinases and their corresponding substrates in multi-tube strips. The kinase stocks are pre-standardized for optimal kinase activity and used for inhibitor profiling using a bioluminescent ADP detection assay. We show that these strips can routinely generate inhibitor selectivity profiles for small or broad kinase family panels. Lipid kinases were also assembled in strip format and profiled together with protein kinases. We identified two specific PI3K inhibitors that have off-target effects on CK2 that were not reported before and would have been missed if compounds were not profiled against lipid and protein kinases simultaneously. To validate the accuracy of the data generated by this method, we confirmed that the inhibition potencies observed are consistent with published values produced by more complex technologies such as radioactivity assays. (C) 2015 The Authors. Published by Elsevier Inc.
引用
收藏
页码:9 / 20
页数:12
相关论文
共 50 条
  • [31] Evaluation of ellagic acid as an inhibitor of sphingosine kinase 1: A targeted approach towards anticancer therapy
    Gupta, Preeti
    Mohammad, Taj
    Khan, Parvez
    Alajmi, Mohamed F.
    Hussain, Afzal
    Rehman, Md Tabish
    Hassan, Md Imtaiyaz
    BIOMEDICINE & PHARMACOTHERAPY, 2019, 118
  • [32] Quantitative kinase inhibitor profiling in native cell and tissue extracts
    Patricelli, Matthew P.
    Nomanbhoy, Tyzoon K.
    Kozarich, John W.
    Gray, Nathanael S.
    Zhang, Jianming
    Wu, Jiangyue
    CANCER RESEARCH, 2010, 70
  • [33] Metabolic profiling of tyrosine kinase inhibitor nintedanib using metabolomics
    Zhou, Zi-Meng
    Wang, Yi-Kun
    Yan, Dong-Mei
    Fang, Jian-He
    Xiao, Xue-Rong
    Zhang, Ting
    Cheng, Yan
    Xu, Kang-Ping
    Li, Fei
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2020, 180
  • [34] Chemical probes for histidine kinase protein profiling and inhibitor discovery
    Carlson, Erin
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
  • [35] Chemoproteomic Method for Profiling Inhibitor-Bound Kinase Complexes
    Fang, Linglan
    Chakraborty, Sujata
    Dieter, Emily M.
    Potter, Zachary E.
    Lombard, Chloe K.
    Maly, Dustin J.
    JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2019, 141 (30) : 11912 - 11922
  • [36] Quantitative kinase inhibitor profiling in native cell and tissue extracts
    Patricelli, Matthew P.
    Nomanbhoy, Tyzoon K.
    Kozarich, John W.
    Gray, Nathanael S.
    Zhang, Jianming
    Wu, Jiangyue
    CANCER RESEARCH, 2010, 70
  • [37] Nilotinib: A Novel, Selective Tyrosine Kinase Inhibitor
    Blay, Jean-Yves
    von Mehren, Margaret
    SEMINARS IN ONCOLOGY, 2011, 38 (02) : S3 - S9
  • [38] Pazopanib: A novel multitargeted tyrosine kinase inhibitor
    Sonpavde G.
    Hutson T.E.
    Current Oncology Reports, 2007, 9 (2) : 115 - 119
  • [39] Lapatinib: a novel dual tyrosine kinase inhibitor
    Simon Chowdhury
    Lisa M. Pickering
    Paul A. Ellis
    Targeted Oncology, 2007, 2 : 107 - 112
  • [40] ROTTLERIN, A NOVEL PROTEIN-KINASE INHIBITOR
    GSCHWENDT, M
    MULLER, HJ
    KIELBASSA, K
    ZANG, R
    KITTSTEIN, W
    RINCKE, G
    MARKS, F
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1994, 199 (01) : 93 - 98